|
|
???tair.name??? >
???browser.page.title.author???
|
"miller v"???jsp.browse.items-by-author.description???
Showing items 11-18 of 18 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-12-02T02:34:40Z |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean J.; Brennan C.; Shih J.-Y.; Riely G.; Viale A.; Wang L.; Chitale D.; Motoi N.; Szoke J.; Broderick S.; Balak M.; Chang W.-C.; Yu C.-J.; Gazdar A.; Pass H.; Rusch V.; Gerald W.; Huang S.-F.; Pan-Chyr Yang; Miller V.; Ladanyi M.; Yang C.-H.; Pao W.; Bean J.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-08-13T06:34:03Z |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean J.; Brennan C.; JIN-YUAN SHIH; Riely G.; Viale A.; Wang L.; Chitale D.; Motoi N.; Szoke J.; Broderick S.; Balak M.; Chang W.-C.; Yu C.-J.; Gazdar A.; Pass H.; Rusch V.; Gerald W.; Huang S.-F.; Yang P.-C.; Miller V.; Ladanyi M.; Yang C.-H.; Pao W.; Bean J.;Brennan C.;Jin-Yuan Shih;Riely G.;Viale A.;Wang L.;Chitale D.;Motoi N.;Szoke J.;Broderick S.;Balak M.;Chang W.-C.;Yu C.-J.;Gazdar A.;Pass H.;Rusch V.;Gerald W.;Huang S.-F.;Yang P.-C.;Miller V.;Ladanyi M.;Yang C.-H.;Pao W. |
| 臺大學術典藏 |
2020-05-26T09:27:24Z |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean J;Brennan C;Shih J.-Y;Riely G;Viale A;Wang L;Chitale D;Motoi N;Szoke J;Broderick S;Balak M;Chang W.-C;Yu C.-J;Gazdar A;Pass H;Rusch V;Gerald W;Huang S.-F;Yang P.-C;Miller V;Ladanyi M;Chih-Hsin Yang;Pao W.; Bean J; Brennan C; Shih J.-Y; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang W.-C; Yu C.-J; Gazdar A; Pass H; Rusch V; Gerald W; Huang S.-F; Yang P.-C; Miller V; Ladanyi M; CHIH-HSIN YANG; Pao W. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
ATLAS: Randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
|
Johnson B.E;Kabbinavar F;Fehrenbacher L;Hainsworth J;Kasubhai S;Kressel B;Lin C.-Y;Marsland T;Patel T;Polikoff J;Rubin M;White L;Chih-Hsin Yang;Bowden C;Miller V.; Johnson B.E; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin C.-Y; Marsland T; Patel T; Polikoff J; Rubin M; White L; CHIH-HSIN YANG; Bowden C; Miller V. |
| 臺大學術典藏 |
2020-05-26T09:27:00Z |
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)
|
Kabbinavar F;Fehrenbacher L;Hainsworth J;Kasubhai S;Kressel B;Marsland T;Patel T;Rubin M;White L;Chih-Hsin Yang;Klughammer B;Colburn D;Miller V;Johnson B.E.; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; CHIH-HSIN YANG; Klughammer B; Colburn D; Miller V; Johnson B.E. |
| 臺大學術典藏 |
2018-09-10T06:32:51Z |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
PAN-CHYR YANG; JIN-YUAN SHIHet al.; CHONG-JEN YU; Bean, J.; Brennan, C.; Shih, J.-Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W.-C.; Yu, C.-J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S.-F.; Yang, P.-C.; Miller, V.; Ladanyi, M.; Yang, C.-H.; Pao, W. |
| 國家衛生研究院 |
2007-12-26 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean, J; Brennan, C; Shih, JY; Riely, G; Viale, A; Wang, L; Chitale, D; Motoi, N; Szoke, J; Broderick, S; Balak, M; Chang, WC; Yu, CJ; Gazdar, A; Pass, H; Rusch, V; Gerald, W; Huang, SF; Yang, PC; Miller, V; Ladany, M; Yang, CH; Pao, W |
| 國家衛生研究院 |
2007-12 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean, J;Brennan, C;Shih, JY;Riely, G;Viale, A;Wang, L;Chitale, D;Motoi, N;Szoke, J;Broderick, S;Balak, M;Chang, WC;Yu, CJ;Gazdar, A;Pass, H;Rusch, V;Gerald, W;Huang, SF;Yang, PC;Miller, V;Ladanyi, M;Yang, CH;Pao, W |
Showing items 11-18 of 18 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
